Effects of daratumumab in treating relapsed and refractory multiple myeloma and its impact on T cell subsets,inflammatory factors,and tumor-associated factors
Objective To investigate the therapeutic effects of daratumumab in patients with relapsed and refractory multiple myeloma (RRMM) and its impact on T cell subsets,inflammatory factors,and tumor-associated factors.Methods A total of 80 RRMM patients treated at our hospitals from January 2022 to January 2024 were selected,and they were divided into a control group (n=40) and an experimental group (n=40) based on whether they received daratumumab.The control group received VRD (bortezomib,lenalidomide,and dexamethasone) treatment,while the experimental group received DVD (daratumumab,bortezomib,and dexamethasone) treatment.The clinical efficacy,T-cell subsets[frequencies of regulatory T cells (Treg),CD3+T cells and CD4+T cells,and the ratio of CD4+/CD8+T cells],inflammatory factors[transforming growth factor-β (TGF-β),interferon-γ (IFN-γ),interleukin-6 (IL-6),and C-reactive protein (CRP)],tumor-associated factors[lactate dehydrogenase (LDH),survivin,vascular endothelial growth factor (VEGF),and β2-microglobulin (β2-MG)],frequency of bone marrow plasma cells,levels of hemoglobin (Hb) and serum M protein,and adverse effects were compared between the groups.Results The overall response rate in the experimental group was higher than that in the control group (P<0.05).The differences in frequencies of Treg,CD3+T cells and CD4+T cells and the ratio of CD4+/CD8+T cells before and after treatment in the experimental group were significantly higher than those in the control group (P<0.05).The differences in levels of TGF-β,IFN-γ,IL-6,and CRP before and after treatment in the experimental group were greater than those in the control group (P<0.05).The differences in levels of LDH,survivin,VEGF,and β2-MG before and after treatment in the experimental group were higher than those in the control group (P<0.05).The differences in the frequency of bone marrow plasma cells and levels of Hb and serum M protein before and after treatment in the experimental group were higher than those in the control group (P<0.05).There was no statistically significant difference between the groups in terms of incidence of leukopenia,thrombocytopenia,fatigue,neuropathic headache,gastrointestinal reactions,and peripheral neuropathy (P>0.05).Conclusions The combination of daratumumab with bortezomib and dexamethasone for treating RRMM effectively improves immune regulation,inflammatory response,tumor suppression,and bone marrow function in patients while maintaining a good safety profile,making it a viable option for further clinical application.
relapsed and refractory multiple myelomadaratumumabT cell subset
维普
万方数据
